Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21871
10.3322/caac.21871 · External reference
10.1126/science.adk0775
10.1126/science.adk0775 · External reference
10.1126/science.adk0850
10.1126/science.adk0850 · External reference
Drugging RAS: Know the enemy
10.1126/science.aam7622 · 2017 · External reference
10.1056/nejmoa2103695
10.1056/nejmoa2103695 · External reference
10.1056/nejmoa2204619
10.1056/nejmoa2204619 · External reference
10.1038/s41586-024-07205-6
10.1038/s41586-024-07205-6 · External reference
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
10.1056/nejmoa2605555 · 2026 · External reference
10.1056/nejmoa2505783
10.1056/nejmoa2505783 · External reference
10.1158/2159-8290.cd-24-0027
10.1158/2159-8290.cd-24-0027 · External reference
10.1038/s41586-024-07379-z
10.1038/s41586-024-07379-z · External reference
10.1093/annonc/mdw008
10.1093/annonc/mdw008 · External reference
10.1038/s41591-026-04537-w
10.1038/s41591-026-04537-w · External reference
Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics
10.1016/j.celrep.2020.03.021 · 2020 · External reference
10.3389/fonc.2024.1380584/bibtex
10.3389/fonc.2024.1380584/bibtex · External reference
10.1158/2159-8290.cd-24-0708
10.1158/2159-8290.cd-24-0708 · External reference
10.1038/s41586-019-1062-1
10.1038/s41586-019-1062-1 · External reference
10.7554/elife.31098
10.7554/elife.31098 · External reference
Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate
10.1158/1078-0432.ccr-25-2333 · 2025 · External reference
10.1074/jbc.272.36.22781
10.1074/jbc.272.36.22781 · External reference
Placental Alkaline Phosphatase Types and Transplacental IgG Transport
2008 · External reference
10.1158/1538-7445.am2020-4552
10.1158/1538-7445.am2020-4552 · External reference
Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer
10.1111/j.1471-0528.1997.tb12061.x · 1997 · External reference
10.1016/j.humpath.2018.11.019
10.1016/j.humpath.2018.11.019 · External reference
Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma
10.1038/s41416-025-03167-2 · 2025 · External reference
10.1016/j.annonc.2022.07.696
10.1016/j.annonc.2022.07.696 · External reference
Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy
10.1016/j.xcrm.2025.102513 · 2025 · External reference
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer
10.1158/0008-5472.can-25-1835 · 2026 · External reference
10.1126/scisignal.adu7145
10.1126/scisignal.adu7145 · External reference
10.1038/s41591-019-0368-8
10.1038/s41591-019-0368-8 · External reference
10.1158/2159-8290.cd-24-0177
10.1158/2159-8290.cd-24-0177 · External reference
mutations, PTMs and recalibrations
2014 · External reference
10.1038/s41586-022-05575-3
10.1038/s41586-022-05575-3 · External reference
Quantitative Temporal Viromics: An Approach to Investigate Host-Pathogen Interaction
2014 · External reference
10.1073/pnas.1808790115
10.1073/pnas.1808790115 · External reference
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets
10.1038/s43018-021-00282-w · 2021 · External reference
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients
10.1093/annonc/mdx542 · 2018 · External reference
Proteomics. Tissue-based map of the human proteome
10.1126/science.1260419 · 2015 · External reference
A pathology atlas of the human cancer transcriptome
10.1126/science.aan2507 · 2017 · External reference
10.1038/s41591-022-02007-7
10.1038/s41591-022-02007-7 · External reference
10.1074/jbc.m009250200
10.1074/jbc.m009250200 · External reference
10.1038/s41568-018-0090-8
10.1038/s41568-018-0090-8 · External reference
10.1016/j.ccr.2014.05.019
10.1016/j.ccr.2014.05.019 · External reference
Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
10.1002/1878-0261.13751 · 2025 · External reference
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
10.1016/j.jbc.2021.101335 · 2021 · External reference
10.1002/ijc.2910330514
10.1002/ijc.2910330514 · External reference
10.1093/nar/gkn316
10.1093/nar/gkn316 · External reference
10.1021/bi061500t
10.1021/bi061500t · External reference
Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment. Antibodies (Basel)
2020 · External reference
10.1158/1078-0432.ccr-11-0488
10.1158/1078-0432.ccr-11-0488 · External reference
10.1158/2159-8290.cd-18-0349
10.1158/2159-8290.cd-18-0349 · External reference
DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity
10.1158/1535-7163.mct-24-0666 · 2026 · External reference
10.1016/j.ccr.2011.03.009
10.1016/j.ccr.2011.03.009 · External reference
10.1038/s41467-024-46811-w
10.1038/s41467-024-46811-w · External reference
Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
10.1016/s1470-2045(24)00636-3 · 2025 · External reference
10.1200/jco.23.02005
10.1200/jco.23.02005 · External reference
342O Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+ metastatic pancreatic adenocarcinoma (mPAC): phase II GLEAM study
10.1016/j.annonc.2026.05.383 · 2026 · External reference
10.1038/s41587-026-03152-x
10.1038/s41587-026-03152-x · External reference
10.1016/j.ccell.2023.07.002
10.1016/j.ccell.2023.07.002 · External reference
10.1158/2159-8290.cd-22-1066
10.1158/2159-8290.cd-22-1066 · External reference
MaxQuant enables high peptide identification rates, individualized p
2008 · External reference
10.1021/pr101065j
10.1021/pr101065j · External reference
10.1093/nar/gky092
10.1093/nar/gky092 · External reference
10.1093/nar/gkv007
10.1093/nar/gkv007 · External reference
Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. Oxford
2005 · External reference
Unresolved reference
External reference
Similarity Analysis by Reciprocal Pairs for Discrete and Continuous Data
10.1177/001316446602600402 · 1966 · External reference
Unresolved reference
External reference
10.1093/database/bau012
10.1093/database/bau012 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1038/ng.3398
10.1038/ng.3398 · External reference
Unresolved reference
External reference
PhosphoNetworks: a database for human phosphorylation networks. Bioinformatics. Oxford
2014 · External reference
10.1002/pro.3978
10.1002/pro.3978 · External reference
10.1016/j.cell.2021.08.023
10.1016/j.cell.2021.08.023 · External reference
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
2016 · External reference
10.1093/nar/gkac382
10.1093/nar/gkac382 · External reference
